藥品參考
Zanidatamab
Zanidatamab is a medicine in the class oncology. It is used for biliary tract cancers.
- 藥物類別: Oncology
- 用途: biliary tract cancers
最後更新 來源: US FDA label, EMA SmPC
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
重點資訊
- 藥物類別
- Oncology
- ATC 代碼
- L01FD07
- 常見劑型
- 注射劑
- 常見規格
- 50 mg/ml
- 已知交互作用
- 1 (中度: 1)
- 商品名
- 2
- 國家與市場
- 2
用途
作用方式
Bispecific HER2-directed antibody binding extracellular domains 2 and 4 of HER2, causing clustering, internalization and receptor reduction; induces CDC, ADCC and ADCP, leading to tumor growth inhibition and cell death.
成人常用劑量（仿單摘要）
GEA, patients <70 kg: 1,800 mg IV every 3 weeks or 1,200 mg every 2 weeks with fluoropyrimidine- and platinum-containing chemotherapy, with or without tislelizumab-jsgr; until disease progression or unacceptable toxicity
懷孕與哺乳
- 懷孕
- Unsafe Can cause fetal harm; not recommended during pregnancy. HER2-directed antibodies have caused oligohydramnios, pulmonary hypoplasia, skeletal abnormalities and neonatal death.
- 哺乳
- Unknown No data on presence in human milk or effects on infant. Weigh benefits of breastfeeding against clinical need; consider half-life of about 24 days and 4-month washout.
已通報的副作用
- Diarrhea
- Nausea
- Decreased appetite
- Vomiting
- Hypokalemia
- Fatigue
黑框警語
- With fluoropyrimidine- and platinum-containing chemotherapy, with or without tislelizumab-jsgr, can cause severe diarrhea, including life-threatening and fatal cases. Use antidiarrheal prophylaxis in the first cycle; interrupt, reduce dose or discontinue based on severity. Exposure during pregnancy can cause embryo-fetal harm; advise of risk and need for effective contraception.
哪些人需要特別留意
- Severe, life-threatening and fatal diarrhea can occur despite loperamide prophylaxis; higher risk with tislelizumab and in patients aged 65 years or older.
- Left ventricular dysfunction: assess LVEF before starting and at regular intervals; safety not established with baseline LVEF below 50%.
- Infusion-related reactions: premedicate, monitor, slow or stop infusion; permanently discontinue for recurrent severe or life-threatening IRRs.
請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏，以及您正在使用的所有其他藥物或保健品。
重要交互作用 (1)
- Fluorouracil + Zanidatamab Moderate
同類別的其他藥品
常見問題
What is Zanidatamab used for?
Zanidatamab is a medicine in the class oncology. It is used for Biliary tract cancers, Gastric cancer.
What side effects have been reported with Zanidatamab?
Diarrhea, Nausea, Decreased appetite, Vomiting, Hypokalemia, Fatigue. Serious warning: With fluoropyrimidine- and platinum-containing chemotherapy, with or without tislelizumab-jsgr, can cause severe diarrhea, including life-threatening and fatal cases.
Can Zanidatamab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm; not recommended during pregnancy. HER2-directed antibodies have caused oligohydramnios, pulmonary hypoplasia, skeletal abnormalities and neonatal death. Breastfeeding: Unknown. No data on presence in human milk or effects on infant. Weigh benefits of breastfeeding against clinical need; consider half-life of about 24 days and 4-month washout.
What does Zanidatamab interact with?
MediHelp lists 1 known interactions for Zanidatamab. Moderate: 1. The most serious include Fluorouracil.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
